Rheumatoid Arthritis in Patients with Sickle Cell Disease: Clinical Challenges and Management Insights from a Case Series in Basrah

The hallmarks of sickle cell disease (SCD), a genetic hemoglobinopathy, include chronic hemolysis, vaso-occlusive crises, and systemic consequences, such as musculoskeletal symptoms that can sometimes resemble those of rheumatoid arthritis (RA). This case series examines the clinical challenges and RA management strategies in five SCD patients, comprising three women and two men, aged 21–52 years. Important observations are the complexity of treatment due to comorbidities such as severe anemia and vaso-occlusive crises, as well as the delayed identification of RA because of symptoms that cross with SCD, like joint pain and inflammation. Patients responded differently to methotrexate (MTX), the major disease-modifying therapy. Two had modest disease activity; others required glucocorticoids or biological agents like rituximab, which sometimes resulted in SCD complications. While it benefited some individuals, the exact function of hydroxyurea was still unknown. Especially, alleviating the anemia caused by Methotrexate (MTX) requires folate supplements. The series stresses the need for a multidisciplinary approach, tailored treatments, and higher suspicion for RA when SCD patients suffer from persistent joint discomfort. These discoveries underline the part that chronic inflammation plays in the pathogenesis of both SCD and RA, therefore stressing the importance of close surveillance and customized treatment to enhance effects.